Nakanoko Tomonori, Koga Tadashi, Taketani Kenji, Hirayama Yoshie, Yoshiya Shohei, Minagawa Ryosuke, Kai Masanori, Kajiyama Kiyoshi, Maehara Yoshihiko
Iizuka Hospital, Fukuoka, Japan.
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Anticancer Res. 2015 Jul;35(7):4135-8.
Small bowel adenocarcinoma is an uncommon disease with poor prognosis. Therefore, characteristics and treatment strategies for small bowel adenocarcinoma should be elucidated sufficiently, not only for surgery, but also for chemotherapy.
Medical records were abstracted to identify patients with small bowel adenocarcinoma who were treated at the Iizuka Hospital, Fukuoka, Japan, between 2004 and 2014. The results of surgical treatment for stage II/III cases and the efficacy of chemotherapy for unresectable stage IV cases were investigated.
The median tumor size was 25.6 ± 19.2 mm, and tumor size was not associated with primary symptoms. Nine of the patients were diagnosed with stage II/III disease and underwent surgical resection. The other three patients were diagnosed with stage IV disease, and two out of those three cases received definitive chemotherapy. In two out of the nine resected cases, recurrence was observed; however, surgical resection of the recurrent tumor was associated with a good prognosis. In stage IV cases that received chemotherapy, survival durations of over 11 months were achieved. In contrast, overall survival in the stage IV case without chemotherapy was 3.3 months.
Curative resection and definitive chemotherapy for unresectable cases are effective treatment strategies for small bowel adenocarcinoma.
小肠腺癌是一种预后较差的罕见疾病。因此，不仅对于手术，而且对于化疗，都应充分阐明小肠腺癌的特征和治疗策略。
提取了2004年至2014年期间在日本福冈饭冢医院接受治疗的小肠腺癌患者的病历。研究了II/III期病例的手术治疗结果以及不可切除的IV期病例的化疗疗效。
肿瘤中位大小为25.6±19.2毫米，肿瘤大小与主要症状无关。9例患者被诊断为II/III期疾病并接受了手术切除。其他3例患者被诊断为IV期疾病，其中3例中的2例接受了根治性化疗。在9例切除病例中的2例中观察到复发；然而，复发性肿瘤的手术切除与良好的预后相关。在接受化疗的IV期病例中，生存期达到了11个月以上。相比之下，未接受化疗的IV期病例的总生存期为3.3个月。
根治性切除和对不可切除病例的根治性化疗是小肠腺癌有效的治疗策略。
